Thursday 13th August 2020 – 17:30 – 18:30
Exploring studies and advances in thoracic oncology showcased at the IASLC WCLC 2020 Virtual Presidential Symposium on 8th August and the potential implications on UK practice.
If you have previously registered at btogwebinars.org (for a previous BTOG webinar), you don't need to re-register, just log in on the day and you'll be able to join the live event.
Chair: Professor Sanjay Popat
The faculty will disseminate the trial data presented, discuss in UK context, and take questions.
Abstract 1: ORIENT-11: Sintilimab + Pemetrexed + Platinum as First-Line Therapy for Locally Advanced or Metastatic Non-Squamous NSCLC
(Speaker: Zhang Li, China)
Abstract 2: Phase 3 Randomized Study of Ensartinib vs Crizotinib in Anaplastic Lymphoma Kinase (ALK)–Positive NSCLC Patients: eXalt3
(Speaker: Leora Horn, USA)
Abstract 3: First-Line Nivolumab + Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma: CheckMate 743
(Speaker: Paul Baas, Netherlands)
Professor Sanjay Popat is Consultant Thoracic Medical Oncologist at the Royal Marsden Hospital and Professor of Thoracic Oncology at the Institute of Cancer Research and Chair of the BTOG Steering Committee
Dr Alastair Greystoke is Clinical Senior Lecturer and Honorary Consultant at the Newcastle University and the Northern Centre for Cancer Care
Professor Fiona Blackhall is Professor of Thoracic Oncology and Honorary Consultant in Medical Oncology at the Christie NHS Foundation Trust
Dr Riyaz Shah is a Consultant Medical Oncologist at Kent Oncology Centre, Maidstone and Tunbridge Wells NHS Trust